 | Up a level |
Koskinas, K C; Gencer, B.; Raeber, L; Karagiannis, A.; Nanchen, D.; Carballo, D.; Carballo, S.; Klingenberg, R.; Heg, D; Matter, C.; Luscher, T.F.; Rodondi, N; Windecker, S; Mach, F. (August 2017). P169 Eligibility for PCSK9 inhibitors according to ESC/EAS and ACC recommendations after acute coronary syndromes. European Heart Journal, 38(suppl_1), ehx501.P169. Oxford University Press 10.1093/eurheartj/ehx501.P169
